Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Antonella Gozzini, Emilio Usala, Angelo M. Carella, Giovanna Rege-Cambrin, Bruno Martino, Elisabetta Abruzzese, Francesco Albano, Fabio Stagno, Luigia Luciano, Mariella D'Adda, Monica Bocchia, Francesco Cavazzini, Mario Tiribelli, Monia Lunghi, Antonietta Pia Falcone, Caterina Musolino, Luciano LevatoClaudia Venturi, Simona Soverini, Michele Cavo, Giuliana Alimena, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, Gianantonio Rosti, Michele Baccarani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The introduction of second-generation tyrosine-kinase inhibitors (TKIs) has generated a lively debate on the choice of first-line TKI in chronic phase, chronic myeloid leukemia (CML). Despite the TKIs have different efficacy and toxicity profiles, the planned use of two TKIs has never been investigated. We report on a phase 2 study that was designed to evaluate efficacy and safety of a treatment alternating nilotinib and imatinib, in newly diagnosed BCR-ABL1 positive, chronic phase, CML patients. One hundred twenty-three patients were enrolled. Median age was 56 years. The probabilities of achieving a complete cytogenetic response, a major molecular response, and a deep molecular response (MR 4.0) by 2 years were 93%, 87%, and 61%, respectively. The 5-year overall survival and progression-free survival were 89%. Response rates and survival are in the range of those reported with nilotinib alone. Moreover, we observed a relatively low rate of cardiovascular adverse events (5%). These data show that the different efficacy and toxicity profiles of TKIs could be favorably exploited by alternating their use.

Original languageEnglish
Pages (from-to)617-622
Number of pages6
JournalAmerican Journal of Hematology
Volume91
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Therapeutics
Cytogenetics
Disease-Free Survival
Survival Rate
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate
Safety
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Gugliotta, G., Castagnetti, F., Breccia, M., Gozzini, A., Usala, E., Carella, A. M., ... Baccarani, M. (2016). Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. American Journal of Hematology, 91(6), 617-622. https://doi.org/10.1002/ajh.24362

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. / Gugliotta, Gabriele; Castagnetti, Fausto; Breccia, Massimo; Gozzini, Antonella; Usala, Emilio; Carella, Angelo M.; Rege-Cambrin, Giovanna; Martino, Bruno; Abruzzese, Elisabetta; Albano, Francesco; Stagno, Fabio; Luciano, Luigia; D'Adda, Mariella; Bocchia, Monica; Cavazzini, Francesco; Tiribelli, Mario; Lunghi, Monia; Pia Falcone, Antonietta; Musolino, Caterina; Levato, Luciano; Venturi, Claudia; Soverini, Simona; Cavo, Michele; Alimena, Giuliana; Pane, Fabrizio; Martinelli, Giovanni; Saglio, Giuseppe; Rosti, Gianantonio; Baccarani, Michele.

In: American Journal of Hematology, Vol. 91, No. 6, 01.06.2016, p. 617-622.

Research output: Contribution to journalArticle

Gugliotta, G, Castagnetti, F, Breccia, M, Gozzini, A, Usala, E, Carella, AM, Rege-Cambrin, G, Martino, B, Abruzzese, E, Albano, F, Stagno, F, Luciano, L, D'Adda, M, Bocchia, M, Cavazzini, F, Tiribelli, M, Lunghi, M, Pia Falcone, A, Musolino, C, Levato, L, Venturi, C, Soverini, S, Cavo, M, Alimena, G, Pane, F, Martinelli, G, Saglio, G, Rosti, G & Baccarani, M 2016, 'Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia', American Journal of Hematology, vol. 91, no. 6, pp. 617-622. https://doi.org/10.1002/ajh.24362
Gugliotta, Gabriele ; Castagnetti, Fausto ; Breccia, Massimo ; Gozzini, Antonella ; Usala, Emilio ; Carella, Angelo M. ; Rege-Cambrin, Giovanna ; Martino, Bruno ; Abruzzese, Elisabetta ; Albano, Francesco ; Stagno, Fabio ; Luciano, Luigia ; D'Adda, Mariella ; Bocchia, Monica ; Cavazzini, Francesco ; Tiribelli, Mario ; Lunghi, Monia ; Pia Falcone, Antonietta ; Musolino, Caterina ; Levato, Luciano ; Venturi, Claudia ; Soverini, Simona ; Cavo, Michele ; Alimena, Giuliana ; Pane, Fabrizio ; Martinelli, Giovanni ; Saglio, Giuseppe ; Rosti, Gianantonio ; Baccarani, Michele. / Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. In: American Journal of Hematology. 2016 ; Vol. 91, No. 6. pp. 617-622.
@article{de2590ad1df9442888a47bec77d5b6c0,
title = "Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia",
abstract = "The introduction of second-generation tyrosine-kinase inhibitors (TKIs) has generated a lively debate on the choice of first-line TKI in chronic phase, chronic myeloid leukemia (CML). Despite the TKIs have different efficacy and toxicity profiles, the planned use of two TKIs has never been investigated. We report on a phase 2 study that was designed to evaluate efficacy and safety of a treatment alternating nilotinib and imatinib, in newly diagnosed BCR-ABL1 positive, chronic phase, CML patients. One hundred twenty-three patients were enrolled. Median age was 56 years. The probabilities of achieving a complete cytogenetic response, a major molecular response, and a deep molecular response (MR 4.0) by 2 years were 93{\%}, 87{\%}, and 61{\%}, respectively. The 5-year overall survival and progression-free survival were 89{\%}. Response rates and survival are in the range of those reported with nilotinib alone. Moreover, we observed a relatively low rate of cardiovascular adverse events (5{\%}). These data show that the different efficacy and toxicity profiles of TKIs could be favorably exploited by alternating their use.",
author = "Gabriele Gugliotta and Fausto Castagnetti and Massimo Breccia and Antonella Gozzini and Emilio Usala and Carella, {Angelo M.} and Giovanna Rege-Cambrin and Bruno Martino and Elisabetta Abruzzese and Francesco Albano and Fabio Stagno and Luigia Luciano and Mariella D'Adda and Monica Bocchia and Francesco Cavazzini and Mario Tiribelli and Monia Lunghi and {Pia Falcone}, Antonietta and Caterina Musolino and Luciano Levato and Claudia Venturi and Simona Soverini and Michele Cavo and Giuliana Alimena and Fabrizio Pane and Giovanni Martinelli and Giuseppe Saglio and Gianantonio Rosti and Michele Baccarani",
year = "2016",
month = "6",
day = "1",
doi = "10.1002/ajh.24362",
language = "English",
volume = "91",
pages = "617--622",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

AU - Gugliotta, Gabriele

AU - Castagnetti, Fausto

AU - Breccia, Massimo

AU - Gozzini, Antonella

AU - Usala, Emilio

AU - Carella, Angelo M.

AU - Rege-Cambrin, Giovanna

AU - Martino, Bruno

AU - Abruzzese, Elisabetta

AU - Albano, Francesco

AU - Stagno, Fabio

AU - Luciano, Luigia

AU - D'Adda, Mariella

AU - Bocchia, Monica

AU - Cavazzini, Francesco

AU - Tiribelli, Mario

AU - Lunghi, Monia

AU - Pia Falcone, Antonietta

AU - Musolino, Caterina

AU - Levato, Luciano

AU - Venturi, Claudia

AU - Soverini, Simona

AU - Cavo, Michele

AU - Alimena, Giuliana

AU - Pane, Fabrizio

AU - Martinelli, Giovanni

AU - Saglio, Giuseppe

AU - Rosti, Gianantonio

AU - Baccarani, Michele

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The introduction of second-generation tyrosine-kinase inhibitors (TKIs) has generated a lively debate on the choice of first-line TKI in chronic phase, chronic myeloid leukemia (CML). Despite the TKIs have different efficacy and toxicity profiles, the planned use of two TKIs has never been investigated. We report on a phase 2 study that was designed to evaluate efficacy and safety of a treatment alternating nilotinib and imatinib, in newly diagnosed BCR-ABL1 positive, chronic phase, CML patients. One hundred twenty-three patients were enrolled. Median age was 56 years. The probabilities of achieving a complete cytogenetic response, a major molecular response, and a deep molecular response (MR 4.0) by 2 years were 93%, 87%, and 61%, respectively. The 5-year overall survival and progression-free survival were 89%. Response rates and survival are in the range of those reported with nilotinib alone. Moreover, we observed a relatively low rate of cardiovascular adverse events (5%). These data show that the different efficacy and toxicity profiles of TKIs could be favorably exploited by alternating their use.

AB - The introduction of second-generation tyrosine-kinase inhibitors (TKIs) has generated a lively debate on the choice of first-line TKI in chronic phase, chronic myeloid leukemia (CML). Despite the TKIs have different efficacy and toxicity profiles, the planned use of two TKIs has never been investigated. We report on a phase 2 study that was designed to evaluate efficacy and safety of a treatment alternating nilotinib and imatinib, in newly diagnosed BCR-ABL1 positive, chronic phase, CML patients. One hundred twenty-three patients were enrolled. Median age was 56 years. The probabilities of achieving a complete cytogenetic response, a major molecular response, and a deep molecular response (MR 4.0) by 2 years were 93%, 87%, and 61%, respectively. The 5-year overall survival and progression-free survival were 89%. Response rates and survival are in the range of those reported with nilotinib alone. Moreover, we observed a relatively low rate of cardiovascular adverse events (5%). These data show that the different efficacy and toxicity profiles of TKIs could be favorably exploited by alternating their use.

UR - http://www.scopus.com/inward/record.url?scp=84967225610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967225610&partnerID=8YFLogxK

U2 - 10.1002/ajh.24362

DO - 10.1002/ajh.24362

M3 - Article

AN - SCOPUS:84967225610

VL - 91

SP - 617

EP - 622

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 6

ER -